Bristol-Myers Squibb Company

Release Summary

BMS-Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) & Rubraca® (Rucaparib)

Bristol-Myers Squibb Company